In a recent Pharmacy Times Q&A, Karen Knudsen, MD, PhD, CEO of the Parker Institute for Cancer Immunotherapy, discussed groundbreaking research evaluating neoadjuvant pembrolizumab for patients with resectable desmoplastic melanoma. The study reported an impressive 70–71% complete response rate after just three doses, highlighting the potential for earlier use of immunotherapy in this historically difficult-to-treat melanoma subtype.
Potential Paradigm Shift in Treatment
Knudsen emphasized that the findings could transform current treatment strategies. “This small study represents an incredible advance. Neoadjuvant PD-1 blockade could become the first-line approach for resectable disease, shifting systemic therapy before surgery rather than reserving it for adjuvant use,” she explained.
The therapy also has the potential to improve surgical outcomes. Desmoplastic melanoma often presents challenges in achieving clear margins. Early immunotherapy may reduce residual microscopic disease at surgery, benefiting both patients and surgical teams. Additionally, patients who respond strongly could experience treatment de-escalation, reducing the intensity of therapy required.
Impact on Patient Outcomes and Quality of Life
The depth of response observed with preoperative pembrolizumab is particularly compelling. Achieving a complete response in roughly 70% of patients after only three doses suggests a potential for long-term disease control. Knudsen noted, “Fewer repeat surgeries and less extensive resections not only improve outcomes but also reduce cosmetic burden, ultimately enhancing patient quality of life.”
Role of Oncology Pharmacists
Pharmacists play a crucial role in implementing neoadjuvant immunotherapy. They can help identify appropriate candidates, educate patients about dosing schedules, expected responses, and potential immune-related toxicities such as rash, fatigue, and diarrhea. Knudsen stressed the importance of maintaining treatment sequencing and preparing for perioperative care to ensure optimal outcomes.
Collaborative Research Models Accelerate Progress
The Parker Institute’s networked approach facilitates rapid data sharing and collaboration, particularly for rare cancers that often lack large-scale clinical studies. “For rare diseases, a tightly aligned network is essential. Our model accelerates the clinic-to-biology feedback loop, de-risks clinical research, and ensures reproducible, high-quality data,” Knudsen said.
This trial, funded by SWOG, involved 10 investigator sites and underscores the value of NIH-supported clinical research in providing advanced cancer care.
Next Steps for Validation
While the initial results are promising, further evidence is needed to confirm neoadjuvant pembrolizumab as a standard of care. Key priorities include assessing the durability of response with longer follow-up, confirming results in larger patient cohorts, and evaluating perioperative safety at scale.
“Although the results are remarkable, prospective validation in larger, comparable datasets will be critical. This will determine if we can replicate these outcomes and establish a new standard for treating desmoplastic melanoma,” Knudsen concluded.
